Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059703 | 0.88 | PLA2G7 (0.44) | NPC1RAB9AHPGDHRH4LMNA | |
| SCHEMBL13635543 | 0.83 | ALKBH5 (0.53) | HPGDLMNAMAPTHTTKMT2A | |
| SCHEMBL10059651 | 0.81 | HRH4 (0.54) | NPC1RAB9AHRH4LMNATP53 | |
| SCHEMBL10059609 | 0.81 | KMT2A (0.47) | NPC1RAB9AHRH4LMNATP53 | |
| SCHEMBL14886291 | 0.79 | HRH4 (0.57) | NPC1RAB9AHRH4HRH3 | |
| SCHEMBL14886545 | 0.79 | HRH4 (0.50) | NPC1RAB9AHRH4KMT2AHRH3 | |
| SCHEMBL10059625 | 0.78 | HRH4 (0.47) | NPC1RAB9AHPGDHRH4LMNA | |
| SCHEMBL17612689 | 0.78 | HRH4 (0.40) | NPC1RAB9AHRH4LMNATP53 | |
| SCHEMBL14886290 | 0.78 | POLB (0.49) | NPC1RAB9AHPGDHRH4TP53 | |
| SCHEMBL10059588 | 0.78 | KMT2A (0.45) | NPC1RAB9AHRH4LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | NPC1 3195/4885RAB9A 2764/4885HPGD 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.